Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H26FN3O4 |
Molecular Weight | 403.4472 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CCN(C1)C2=C(OC)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O)[C@H](C)NC
InChI
InChIKey=SUQUWONDIBHQOZ-NWDGAFQWSA-N
InChI=1S/C21H26FN3O4/c1-11(23-2)12-6-7-24(9-12)18-16(22)8-14-17(20(18)29-3)25(13-4-5-13)10-15(19(14)26)21(27)28/h8,10-13,23H,4-7,9H2,1-3H3,(H,27,28)/t11-,12+/m0/s1
Molecular Formula | C21H26FN3O4 |
Molecular Weight | 403.4472 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Premafloxacin is an 8-methoxy fluoroquinolone derivative patented by American pharmaceutical company Warner-Lambert Co. as an antibacterial agent. In preclinical studied. Premafloxacin was equivalent to ciprofloxacin, enrofloxacin, and danofloxacin in activity against the gram-negative bacilli but was much more active than the comparison antimicrobial agents (against the staphylococci, streptococci, and anaerobes. Premafloxacin acts as a topoisomerase IV inhibitor with enhanced activity against Staphylococcus aureus.
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:42:41 GMT 2023
by
admin
on
Sat Dec 16 05:42:41 GMT 2023
|
Record UNII |
UOM2HMO524
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
100000081427
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
C105016
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
C66464
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
DTXSID70162407
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL2105374
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
71455
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
SUB10025MIG
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
143383-65-7
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
7333
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
GG-29
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY | |||
|
UOM2HMO524
Created by
admin on Sat Dec 16 05:42:41 GMT 2023 , Edited by admin on Sat Dec 16 05:42:41 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|